Overcoming drug delivery barriers to Unlock the therapeutic potential of conventional chemotherapy in glioblastoma
Biochemical Pharmacology · 2026-12 · 254 · 118552
DOI: 10.1016/j.bcp.2026.118552 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-12. Verfasst von Kecheng Qian und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China. Die Arbeit nennt 146 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Glioblastoma (GBM) remains one of the most incurable malignancies, and systemic therapies continue to provide only limited clinical benefit despite encouraging preclinical evidence. Therapeutic failure has traditionally been attributed to insufficient drug efficacy or intrinsic resistance mechanisms. However, increasing evidence suggests that many conventional chemotherapeutic agents retain substantial antitumor activity but fail to achieve sufficient intratumoral exposure because of delivery barriers. This review proposes that inadequate drug delivery represents a major barrier limiting the therapeutic efficacy of conventional chemotherapeutics in GBM, independent of their intrinsic pharmacodynamic activity. We re-evaluate conventional chemotherapeutic agents, including alkylating agents, microtubule-targeting agents, topoisomerase inhibitors, and platinum compounds, from the perspective of blood-brain barrier (BBB) transport, heterogeneous intratumoral drug distribution, and dose-limiting systemic toxicity. We further discuss how emerging drug delivery strategies can restore the therapeutic potential of these agents by improving brain penetration and intratumoral distribution without altering their intrinsic pharmacological properties.By reframing chemotherapy failure in GBM as a consequence of both pharmacodynamic resistance and inadequate drug delivery, this Review highlights drug delivery as an underappreciated determinant of therapeutic efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
- The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China; The Third Affiliated Hospital of Zhejiang, Chinese Medical University, H…
- The Third Affiliated Hospital of Zhejiang, Chinese Medical University, Hangzhou, Zhejiang, 310005, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Qian, K., Cen, X., Zhao, Y., Xuan, Z., Jia, Z., Jiang, T., Ma, C., Di, Z., Zhang, W., & Lin, X. (2026). Overcoming drug delivery barriers to Unlock the therapeutic potential of conventional chemotherapy in glioblastoma. Biochemical Pharmacology, 254, 118552. https://doi.org/10.1016/j.bcp.2026.118552
Vancouver
Qian K, Cen X, Zhao Y, Xuan Z, Jia Z, Jiang T, et al. Overcoming drug delivery barriers to Unlock the therapeutic potential of conventional chemotherapy in glioblastoma. Biochemical Pharmacology. 2026;254:118552. doi:10.1016/j.bcp.2026.118552
BibTeX
@article{Qian2026,
author = {Qian, Kecheng and Cen, Xiaokai and Zhao, Yuhui and Xuan, Ziqi and Jia, Zhaoxing and Jiang, Tianxiang and Ma, Congcong and Di, Zhong and Zhang, Weiping and Lin, Xianming},
title = {Overcoming drug delivery barriers to Unlock the therapeutic potential of conventional chemotherapy in glioblastoma},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {254},
pages = {118552},
doi = {10.1016/j.bcp.2026.118552}
}
EUVIMED